Health Care • Biotechnology: Pharmaceutical Preparations
$3.87 ▼ -0.12
(-3.00%)
MKT CAP: $33.1M • VOL: 23.9K
52W L $2 52W H $11
IBO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $32.0K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | -$392.0K | — | — |
| Gross Margin % | -50.0% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.3M | -$28.8M | -$4.0M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$11.8M | -$24.7M | -$4.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.9M | -$2.9M | -$2.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$1.9M | -$2.9M | -$2.9M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -27.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.0K | $2.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $12.3M | $4.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IBO.